FDA rejects Biohaven's ataxia drug, shutting down company's second attempt to win approval

The FDA has turned down Biohaven’s drug for spinocerebellar ataxia, a neurodegenerative disease that leads to loss of coordination and balance, citing issues with using real-world evidence and natural history studies. As a result, Biohaven ...